Gene editing is changing the world. Founded by pioneers in the CRISPR/CAS revolution, Metagenomi is discovering the next generation of gene-editing systems for use in treating genetic diseases.

Ionis Pharmaceuticals

Cystic Fibrosis Foundation

Sozo Ventures

Agent Capital

RA Capital Management

Leaps by Bayer

HOF Capital

Humboldt Fund

InCube Ventures

Yaya Capital

Surveyor Capital

Novo Holdings

Marshall Wace

Millennium Management

Bristol Myers Squibb

Deep Track Capital

Eventide

Farallon Capital Management

Frazier Healthcare Partners

SymBiosis LLC

Catalio Capital Management

Moderna

Metagenomi

From our team to yours, we wish you a safe and joyful holiday season. As we wind down for our annual winter break, we look forward to what’s to come in the new year.

During AIChE's 6th International Conference on CRISPR Technologies, which took place October 17-19th in Boston, MA, Metagenomi gave one oral presentation and two poster presentations.  What scientific findings did we present at this conference?

Last year, we published new data in Nature Portfolio describing novel, compact RNA-guided nucleases used to develop the smallest adenine base editor (ABE) to date. This ABE, at just 623 amino acids in size, is highly active in cells.

Metagenomi’s discovery could potentially enable novel in vivo delivery options for our precision genetic medicines. To learn more about Metagenomi's discovery platform, visit our website, and see the link below to learn more about our findings. 

Read more: https://lnkd.in/gebRnH5K

Today’s historic FDA approval of the first CRISPR-based therapy is a remarkable step forward for both sickle cell patients and the field of gene editing. We wholeheartedly celebrate this major milestone and congratulate the countless scientists and researchers dedicated to creating curative genetic medicines for patients in need.

https://lnkd.in/gWdrjeun

At Metagenomi, we believe that our values are foundational to who we are as an organization. In October we internally debuted the new set of company values that are reflective of our shared vision and commitment to excellence, and will guide us on our journey ahead.

With extensive input from our employees and executive team, we've distilled our core principles into three pillars that shape our identity:

-Driven by innovation
-Dedicated to scientific rigor
-Championed by each other

At the internal unveiling event, we celebrated our corporate values through historical recount and storytelling of Metagenomi's evolution, describing key moments that have informed our distinct culture. Check a photo from the event below, and visit https://lnkd.in/gJUhW6FJ to learn more.

Metagenomi is presenting during the 4th annual CRISPR 2.0 Congress from November 28-30th in Boston, MA. On Thursday, November 30th, Metagenomi will be giving two presentations:

Alan Brooks will be presenting ‘A Novel Type V CRISPR System With Potent Editing Activity in Mice and Non-Human Primates’ at 11:45 am ET . 

Chris Brown will be giving a talk titled ‘Enabling Rapid Discovery and Development of Next-Generation Genome Editing Tools Through Metagenomics’ at 3:45 pm ET.

Happy Thanksgiving! We're thankful for the incredible team at Metagenomi who work tirelessly every day to create poten­tial­ly cura­tive ther­a­peu­tics. 

#Metagenomi #HappyThanksgiving

At Metagenomi, our ultra-small nucle­as­es are high­ly effi­cient genome edit­ing sys­tems that have the poten­tial for exten­sive ther­a­peu­tic appli­ca­tions. We have pri­or­i­tized find­ing sys­tems to over­come the size con­straints of first gen­er­a­tion nucle­as­es. Our sys­tems are a frac­tion of the size and pack­age eas­i­ly into a sin­gle AAV for tar­get­ing organs beyond what is pos­si­ble with lipid nanopar­ti­cle delivery.

Learn more about our systems: https://lnkd.in/gyxsjbYB 

#Metagenomi

Today, the UK officially authorized the very first CRISPR-based gene editing therapy for use. This is a momentous day for our field and a huge step forward in paving the way for curative genetic medicines to become standardized treatments. Of course, this is an exciting day for the field, but moreover, its an astounding win for patients and families.

https://lnkd.in/ezKhAzkq

Today, Metagenomi announced the appointment of Luis Borges, Ph.D., as Chief Scientific Officer and Pamela Wapnick, MBA, as Chief Financial Officer.

“I am excited to welcome Luis and Pamela to expand the scientific and financial strength of our leadership team,” said Brian C. Thomas, Ph.D., CEO and founder of Metagenomi. “The talent, experience, and in-depth knowledge that Luis and Pamela bring will be instrumental in the execution of our strategy at a time when Metagenomi is rapidly advancing multiple therapeutic programs towards clinical development. I am proud of the world-class team we have assembled, driven by our passion and commitment to develop curative therapeutics for patients using our proprietary, metagenomics-derived genome editing toolbox.”

Read more about this appointment in our latest press release: https://lnkd.in/gvMuCU8h

Senior Director, Analytical Sciences & Quality Control

Head, Analytical Sciences

Director, AAV Process and Analytical Development

Manager

Senior Director, Analytical Sciences & Quality Control at Metagenomi

Kok-Seong Lim

Director Program Management

Contract Project Manager

Senior Project Portfolio Manager

Senior Program Manager

Program Manager

Donella Meadows Sustainability Leadership Fellow

Sr EHS Specialist

Business Analyst

Director Program Management Drug Discovery and Early Development

Tse-Sung Wu

Associate Director, Cell Therapy

Associate Director, Research & Site Head, Century Therapeutics Canada

CoFounder & Director, Preclinical Development

Program Director

Program Scientist

Post Doctoral Fellow

Teaching Assistant

PHD Student

Parvez Vora

Director, Novel Delivery Technologies for Genetic Medicines

Chemistry of LNPs for RNA Delivery  | Target Validation | Treg Cell Therapy

Senior Scientist

Scientist

Center for Systems Biology Research Scientist

Post Doctoral

Cell and Gene Therapy | Immunology | RNA Delivery | Nanoparticles | Chemistry

Carlos Tassa

Associate Director

Senior Researcher

Postdoctoral position

Postdoc

PhD student

Cindy Castelle

DIrector, Process Engineering, Tech-Ops

Associate Director, Process Development and Validation

Senior Process Engineer, Cell Culture and Purification

Process Engineer, Cell Culture

Cell Culture, Lead Master Associate

Cell Culture, Senior Associate

Cell Culture Associate Scientist

Cell Culture Manufacturing Associate

Internship

Assistant to Director of Engineering and Director of Marketing

Anil Chhibbar

Executive Board Director

President/COO

Member of SAB

Member Of SAB

Interim COO

President/COO and Board Director at Metagenomi / Women in Biopharma ‘22 / Biopharma Veteran

Jian Irish

Associate Director of FP&A

Associate Director, FP&A

Associate Director of Finance, Commercial FP&A

Finance Manager, Financial Planning & Analysis - Commercial Operations Lead

Manager, Financial Planning & Analysis

Sr. Financial Analyst

Project Manager, Quality Process Improvement & QA Compliance

Project Manager, Quality Operations

Finance Manager/Sr. Financial Analyst

Associate Director, FP&A - at Metagenomi

Tony Tse

Senior Director, Total Rewards

Director Total Rewards

Sr. Manager, Total Rewards

Senior Manager Compensation and Benefits

Sr. Manager, Global Benefits and Mobility

Benefits Manager

Senior Manager, Benefits

Benefits  Manager & Payroll Administrator

Insurance Manager

Human Resources Generalist

Benefits Coordinator

Benefits Administrator

Human Resources Assistant

Human Resource Assistant/Internship Coordinator

Julie Huang

Chief Scientific Officer

Chief Scientific Officer at Century Therapeutics

SVP Research

VP Immuno-Oncology Research

Executive Director

Scientific Director

Principal Scientist

Research Scientist

Post-doctoral scientist

Chief Scientific Officer at Metagenomi

Luis Borges

Associate Director, Analytical Development

Senior Research scientist

Howard Yu

Director Program Management and Business operations

Associate Director, R&D project management

Associate Director Project Management

Project Manager

Project Manager, Medical Affairs Operations

Director of Project Management

Sonya Cruz

CMC and CMO Management

Supply Chain Director

Sr. Manager, Sourcing & Supplier Management

Quality Assurance Consultant Specialist

Global Planning and Logistics PM - (Contract Work)

External Manufacturing and Collaboration Management at Metagenomi Inc

Maravilla Rasalan

Associate Director, Program Management

Senior Manager, CMC Project Management

Project Manager, CMC Regulatory

Senior BioProcess Engineer

BioProcess Engineer

Chemical Research II, Process Engineer

Research Assistant

Graduate Assistant

Teacher Assistant

PROCESS ENGINEERING INTERN, ENVIRONMENTAL HEALTH AND SAFETY (EH&S) ENGINEER,

Sogol Hekmatfar

Senior Director of Biochemistry and Characterization

Senior Director of Biochemistry and Protein Engineering

Director of Early Biology

Scientist II

Postdoctoral Scholar

Senior Director of Biochemistry and Characterization at Metagenomi

Cristina Butterfield

Chief Investment Officer

Senior Vice President, Corporate Strategy and Finance

Vice President, Corporate Strategy and Finance

Vice President

Associate

Chief Investment Officer at Metagenomi | building and funding next-generation biotech companies

industry trends dossier	dataroom
company dossier	dataroom
network	dataroom
network mapping	dataroom
transactions dossier	dataroom
network onboarding	dataroom
news impact assignment basic	general
public peers	general
news daily refresh	general	Aug 31, 2024 10:00 AM	eae58810
news processing daily refresh	general	Aug 30, 2024 4:17 AM	0f7418f5
news impact assignment daily	general	Aug 30, 2024 8:38 AM	08290bdb
news processing basic	general
company summary	general	Aug 30, 2024 12:00 PM	6861fad3
signals	general
news advanced	general
news impact assignment advanced	general
news processing advanced	general
peers	general	Feb 5, 2024 8:46 PM	03559ce6
news basic	general
events	markdown
bundesanzeiger	filings
financial statements	filings
regulatory analysis	company_analysis
industry analysis	company_analysis
competition analysis	company_analysis
financial legal advisories	company_analysis
merger acquisitions	company_analysis
swot analysis	company_analysis
financial analysis	company_analysis
purchaser profile	merger_acquisitions
customer profile	customers

MGX

CO:METAGENOMI

Metagenomi

Last Close

2.98

30/08 20:00

Market Cap

162.97M

Beta: -

Volume Today

74.23K

Avg: -